UBS Group’s Agios Pharmaceuticals AGIO Stock Holding History

UBS Group’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-50,000	Closed	-$1.77M	–	7897
2020 Q1	$1.77M	Hold	50,000	–	–	﹤0.01%	2864
2019 Q4	$2.39M	Buy	+50,000	New	+$1.89M	﹤0.01%	3379
2017 Q2	–	Sell	-28,200	Closed	-$1.65M	–	7625
2017 Q1	$1.65M	Buy	+28,200	New	+$1.35M	﹤0.01%	3117
2016 Q2	–	Sell	-65,000	Closed	-$2.64M	–	7681
2016 Q1	$2.64M	Buy	+65,000	New	+$2.78M	﹤0.01%	2419
2015 Q3	–	Sell	-100	Closed	-$11K	–	8373
2015 Q2	$11K	Sell	100 -300	-75%	-$32.3K	﹤0.01%	7376
2015 Q1	$38K	Sell	400 -100	-20%	-$11.2K	﹤0.01%	6296
2014 Q4	$56K	Buy	+500	New	+$44.6K	﹤0.01%	6349

Other funds holding AGIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

UBS Group's AGIO Position: Q1 2026 in Review

UBS Group increased its Agios Pharmaceuticals (AGIO) stake by 4.6% in Q1 2026, buying an estimated $167K and bringing the position to 132,540 shares worth $4.48M. The position accounts for ﹤0.01% of the portfolio, ranked #4180.

UBS Group first reported a position in AGIO in Q4 2014 and has held it in 46 quarters since. The position peaked at $16.6M in Q4 2014. 233 funds tracked by Wall St. Rank hold AGIO as of Q1 2026.

UBS Group held 132,540 shares of Agios Pharmaceuticals worth $4.48M as of Q1 2026.
UBS Group bought 5,875 Agios Pharmaceuticals shares in Q1 2026, an estimated $167K.
Agios Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #4180 holding.
UBS Group first reported a position in Agios Pharmaceuticals in Q4 2014 and has held it in 46 quarters since.
UBS Group's Agios Pharmaceuticals position peaked at $16.6M in Q4 2014.
233 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.